Response to venetoclax correlated with higher BCL2:MCL1 and BCL2:BCL2L1 mRNA expression ratios as confirmed by biomarker analysis (BCL2 overexpression, BCL2L1 (coding for Bcl-xL) downregulation); these ratios are essential response predictors for venetoclax and were significantly higher in t(11:14) MM cells compared to MM cells without t(11:14) translocation (116, 123). This evidence concerns the gene BCL2L1 and Miyoshi myopathy.